Floatz logo

Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa

Esophageal Cancer

Explore 131 assets in Esophageal Cancer →
Floatz Rating
CCC48/100
Confidence
Indicative
v0.2
Sponsor
Cancer Research UK
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05057013CT.gov
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Esophageal Cancer

AssetSponsorPhaseRating
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa (this asset)Cancer Research UKP1/2CCC · 48
Tisotumab VedotinSeagen Inc.P2BB
FluorouracilumMerck Sharp & Dohme LLCP4BB
EpirubicinSutro Biopharma, Inc.P3B
PembrolizumabEssen BiotechP3B
CetirizineCiusss de L'Est de l'Île de MontréalP3B
DocetaxelLaekna LimitedP2B
CapecitabineShenyang Sunshine Pharmaceutical Co., LTD.P2B
CyclophosphamideSutro Biopharma, Inc.P3B

+42 more in the Esophageal Cancer cohort

Other indications for Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa

IndicationSponsorPhaseRating
Head And Neck Squamous Cell Carcinoma—P1/2CCC · 48
Esophageal Squamous Cell Carcinoma—P1/2CCC · 48
Skin Squamous Cell Carcinoma—P1/2CCC · 48

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa in Esophageal Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/gamma1-heavy-chain-humanized-1-450-vh-homo-sapiens-ighv4-3101-899-ighd-ighj401-929-cdr-imgt-9713-26-3452-5897-109-1-120-homo-sapiens-ighg101-100-g1m171-ch1-k120-d12-l14-ch1-k120-217-121-218-hinge-1-15-219-233-ch2-234-343-ch3-d12-359-l14-361-344-448-chs-449-450-121-450-223-214-disulfide-with-kappa-light-chain-humanized-1-214-v-kappa-homo-sapiens-igkv1-1201-853-igkj201-100-cdr-imgt-639-27-3250-5289-97-1-107-homo-sapiens-igkc01-100-km3-a451-153-v101-191-108-214-dimer-229-229232-232-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-derived-from-the-cell-line-cho-k1glycoform-alfa-esophageal-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →